Skip to content
DataLookout
Menu

NCT07928388

Continuation Study With Oral MC-1 for Treatment of Patients With PNPO-Deficiency

StatusRecruiting
PhasePhase 3
SponsorMedicure
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Timeframe: Through study completion, up to 4 years

Arms and interventions

Treatment ArmExperimental

Oral MC-1

Drugs: Pyridoxal 5'-Phosphate

Sites

5 sites in 2 countries

United States 3, Australia 2